Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological case-control approaches.
Paulina Gomez-RubioJanet PiñeroEsther Molina-MontesAlba Gutiérrez-SacristánMirari MarquezMarta RavaChristoph W MichalskiAntoni FarréXavier MoleroMatthias LöhrJosé PereaWilliam GreenhalfMichael O'RorkeAdonina TardónThomas GressVictor M BarberáTatjana Crnogorac-JurcevicLuís Muñoz-BellvísEnrique Domínguez-MuñozJoaquim BalsellsEithne CostelloJingru YuMar IglesiasLucas IlzarbeJörg KleeffBo KongJosefina MoraLiam MurrayDamian O'DriscollIgnasi PovesRita T LawlorWeimin YeManuel HidalgoAldo ScarpaLinda SharpAlfredo CarratoFrancisco X RealLaura I FurlongNúria Malatsnull nullPublished in: International journal of cancer (2018)
Deciphering the underlying genetic basis behind pancreatic cancer (PC) and its associated multimorbidities will enhance our knowledge toward PC control. The study investigated the common genetic background of PC and different morbidities through a computational approach and further evaluated the less explored association between PC and autoimmune diseases (AIDs) through an epidemiological analysis. Gene-disease associations (GDAs) of 26 morbidities of interest and PC were obtained using the DisGeNET public discovery platform. The association between AIDs and PC pointed by the computational analysis was confirmed through multivariable logistic regression models in the PanGen European case-control study population of 1,705 PC cases and 1,084 controls. Fifteen morbidities shared at least one gene with PC in the DisGeNET database. Based on common genes, several AIDs were genetically associated with PC pointing to a potential link between them. An epidemiologic analysis confirmed that having any of the nine AIDs studied was significantly associated with a reduced risk of PC (Odds Ratio (OR) = 0.74, 95% confidence interval (CI) 0.58-0.93) which decreased in subjects having ≥2 AIDs (OR = 0.39, 95%CI 0.21-0.73). In independent analyses, polymyalgia rheumatica, and rheumatoid arthritis were significantly associated with low PC risk (OR = 0.40, 95%CI 0.19-0.89, and OR = 0.73, 95%CI 0.53-1.00, respectively). Several inflammatory-related morbidities shared a common genetic component with PC based on public databases. These molecular links could shed light into the molecular mechanisms underlying PC development and simultaneously generate novel hypotheses. In our study, we report sound findings pointing to an association between AIDs and a reduced risk of PC.